Healthcare ❯ Pharmaceuticals ❯ Vaccines

COVID-19 Vaccines

Protein-based Vaccines Novavax Approval Process mRNA Vaccines Pfizer Inc. Pfizer-BioNTech Vaccine

Pfizer Sets 2026 Targets Below Wall Street as COVID Sales Fade, Patent Pressure Builds

Executives blame weaker COVID demand alongside pending patent losses, signaling a near-term reset toward pipeline investment.

Pfizer’s Updated COVID-19 Vaccine Shows Strong Phase 3 Immune Response for 2025–2026 Formula